Previous studies by ourselves and others have shown that treatment with DAC ameliorates the course of rodent models of autoimmune diseases, such as type 1 diabetes, MS, and Guillain Barrè syndrome (GBS), likely by inducing the upregulation of FoxP3 expression and induction of regulatory T cells [23,24,25,26,27]. This evidence concerns the gene FOXP3 and Guillain-Barre syndrome.